title: Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
abstract: The effect of short-term bezafibrate (BF) administration over time on the expression of adiponectin mRNA in the tissues was examined in Otsuka Long Evans Tokushima Fatty (OLETF) rats. Eight-week-old rats were divided into the high-dose (100 mg/kg) BF group (n=15), the low-dose (10 mg/kg) BF group (n=15), or the control group (n=15) and followed up for 14 d. Tri-glyceride and free fatty acid levels significantly decreased in a dose-dependent manner in the high-dose BF group. The insulin levels increased with time, although they were significantly lower in the high-dose BF group on d 3 and 7 than the control group. Adiponectin levels significantly increased in the high-dose BF group. On d 14 of BF administration, the levels of VLDL and chy-lomicron were significantly lower in BF groups, and adiponectin mRNA expression in the white adipose tissue was significantly higher in the high-dose BF group. Findings from this study suggest that in type 2 diabetes with insulin resistance, hypertriglyceridemia is closely linked to adiponectin.
authors.affiliation: Department of Internal Medicine, National Hospital Organization, Utsunomiya National Hospital, Japan. moriyutakajp@yahoo.co.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Mori
authors.forename: Fumiki
authors.initials: F
authors.lastname: Oana
authors.forename: Akane
authors.initials: A
authors.lastname: Matsuzawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Akahane
authors.forename: Naoko
authors.initials: N
authors.lastname: Tajima
mesh_terms: D052242:Adiponectin; D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D001629:Bezafibrate / Q000008:administration & dosage*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015243:Cholesterol, VLDL / Q000097:blood / Q000187:drug effects; D002914:Chylomicrons / Q000097:blood / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism; D008297:Male; D009765:Obesity / Q000150:complications / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D020334:Rats, Inbred OLETF
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D015243:Cholesterol, VLDL; D002914:Chylomicrons; D000960:Hypolipidemic Agents; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; D001629:Bezafibrate